Kailera's oral weight loss pill met its trial goal, but nausea hit 70% of patients
Kailera stock dropped 10% after Phase 3 data showed roughly 70% of patients on HRS-7535 experienced nausea
Overview
Kailera stock dropped 10% after Phase 3 data showed roughly 70% of patients on HRS-7535 experienced nausea
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.